Skip to main content
. 2022 May 17;12:8195. doi: 10.1038/s41598-022-10578-1

Figure 4.

Figure 4

Total number of injections over the 1-year study period in 45 eyes with neovascular age-related macular degeneration associated with type 1 macular neovascularization treated with 3 monthly intravitreal injections of brolucizumab followed by a treat-and-extend regimen with intravitreal brolucizumab.